Pakistan Pharmaceuticals: FEROZ & BFBIO: Analyst briefing takeaways – By Insight Research
Nov 27 2024
Insight Securities
- Ferozsons Laboratories Limited & BF Biosciences held its analyst briefing to comment on their financial result and to shed light on future outlook. Highlights of the session are given below:
- Production from BFBIO’s Line 2 which is dedicated to prefilled syringes has commenced. From the next quarter, depreciation would be realized for this line. The combo line and lyophilization line are currently in the validation phase.
- The company emphasized that semaglutide is a highly profitable product, boasting a margin of 40-50%. To highlight, Semaglutide is not a perfect substitute for type 1 diabetes but can effectively be used for type 2 diabetes.